ProKidney (PROK) to Release Quarterly Earnings on Friday

Key Points

• ProKidney (NASDAQ:PROK) is set to announce its Q2 2025 earnings on Friday, August 8th, with analysts forecasting a loss of ($0.14) per share.
• In their last earnings report, ProKidney reported a loss of ($0.13) per share, outperforming expectations by $0.03, with revenue of $0.23 million.
• Analysts have mixed ratings for ProKidney, with recent upgrades from several firms raising price targets, while Bank of America downgraded the stock from "neutral" to "underperform".

ProKidney (NASDAQ:PROK - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Friday, August 8th. Analysts expect ProKidney to post earnings of ($0.14) per share for the quarter.

ProKidney (NASDAQ:PROK - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.03. The business had revenue of $0.23 million for the quarter. On average, analysts expect ProKidney to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ProKidney Price Performance

Shares of NASDAQ:PROK traded up $0.15 during trading hours on Monday, hitting $2.97. 1,559,581 shares of the company's stock traded hands, compared to its average volume of 5,947,624. ProKidney has a 1 year low of $0.46 and a 1 year high of $7.13. The business has a fifty day moving average price of $1.78 and a 200-day moving average price of $1.33. The firm has a market capitalization of $869.32 million, a P/E ratio of -4.95 and a beta of 1.76.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on PROK. UBS Group boosted their target price on ProKidney from $4.00 to $8.00 and gave the company a "buy" rating in a research report on Tuesday, July 15th. Wall Street Zen upgraded ProKidney from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Bank of America lowered ProKidney from a "neutral" rating to an "underperform" rating and dropped their target price for the company from $3.00 to $1.00 in a research report on Monday, June 30th. Citigroup reaffirmed a "buy" rating and set a $9.00 target price (up from $6.00) on shares of ProKidney in a research report on Wednesday, July 9th. Finally, Guggenheim reaffirmed a "buy" rating and set a $7.00 target price (up from $6.00) on shares of ProKidney in a research report on Monday, July 14th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $6.25.

Insider Activity at ProKidney

In other news, insider Darin J. Weber sold 103,480 shares of the firm's stock in a transaction that occurred on Tuesday, July 8th. The shares were sold at an average price of $3.02, for a total transaction of $312,509.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 41.49% of the company's stock.

Hedge Funds Weigh In On ProKidney

A hedge fund recently raised its stake in ProKidney stock. AQR Capital Management LLC boosted its holdings in shares of ProKidney Corp. (NASDAQ:PROK - Free Report) by 106.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 52,570 shares of the company's stock after buying an additional 27,098 shares during the quarter. AQR Capital Management LLC's holdings in ProKidney were worth $46,000 as of its most recent SEC filing. Institutional investors and hedge funds own 51.59% of the company's stock.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.